ArticleCureus2026
National and Regional Trends in Hemorrhagic Stroke Mortality in Brazil, 2000-2023.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Hemorrhagic stroke contributes disproportionately to stroke-related mortality and disability. This study examined national, regional, and sex-specific trends in hemorrhagic stroke mortality among Brazilian adults from 2000 to 2023 and assessed whether these trends changed during the COVID-19 pandemic. Materials and methods We conducted a population-based ecological time-series study using data from the Brazilian Mortality Information System. Deaths among adults aged 20 years or older were identified by International Classification of Diseases, 10th Revision codes I60-I62. Crude and age-standardized mortality rates were calculated per 100,000 population. Direct standardization used the age distribution of the 2022 Brazilian Census population. Weighted log-linear regression was used to estimate annual percentage changes (APCs) and 95% confidence intervals (CIs). Temporal slopes were compared by sex and geographic region. An interrupted time-series analysis with a fixed breakpoint at 2020 assessed immediate and postpandemic changes. Sensitivity analyses excluded 2020 and 2021 and compared crude with age-standardized rates. Results Between 2000 and 2023, 500,301 hemorrhagic stroke deaths were recorded. Annual deaths increased from 17,846 to 23,945, whereas the age-standardized mortality rate declined from 22.3 to 14.8 per 100,000 population. Mortality decreased nationally (APC, -2.09%; 95% CI, -2.36% to -1.82%) and among both men (APC, -1.98%; 95% CI, -2.25% to -1.71%) and women (APC, -2.18%; 95% CI, -2.47% to -1.90%). Regional trends differed: mortality was statistically stable in the North (APC, -0.08%; 95% CI, -0.51% to 0.35%) and Northeast (APC, -0.40%; 95% CI, -0.84% to 0.05%) and decreased in the Southeast, South, and Central-West. The interrupted time-series analysis found no significant immediate change in national mortality in 2020 (-6.3%; 95% CI, -15.6% to 4.2%). Excluding 2020 and 2021 did not materially change the direction or statistical classification of the national trend. Conclusions Age-standardized hemorrhagic stroke mortality declined in Brazil despite an increase in the absolute number of deaths, indicating that population growth and aging increased the mortality burden while age-specific risk decreased. National improvement concealed substantial regional disparities, with substantially less favorable trends in the North and Northeast than in the Southeast, South, and Central-West. These findings support prioritizing regional investigation of hypertension control, access to organized stroke care, and cause-of-death classification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.